Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Lauren C. Seeberger & Robert A. Hauser. (2017) Valbenazine for the treatment of tardive dyskinesia. Expert Opinion on Pharmacotherapy 18:12, pages 1279-1287.
Read now
Read now
Daniel P. Witter, Richard C. Holbert & Uma Suryadevara. (2017) Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients. Expert Opinion on Pharmacotherapy 18:10, pages 965-972.
Read now
Read now
Hani Raoul Khouzam. (2015) Identification and management of tardive dyskinesia: A case series and literature review. Postgraduate Medicine 127:7, pages 726-737.
Read now
Read now
Jonathan Tomas Lockwood & Gary Remington. (2015) Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials. Expert Opinion on Emerging Drugs 20:3, pages 407-421.
Read now
Read now
Thomas Müller. (2015) Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert Opinion on Investigational Drugs 24:6, pages 737-742.
Read now
Read now
Articles from other publishers (36)
Jaiyeola Abiola Kajero, Soraya Seedat, Jude U. Ohaeri, Abidemi Akindele & Oluwagbemiga Aina. (2022) The effects of cannabidiol on behavioural and oxidative stress parameters induced by prolonged haloperidol administration. Acta Neuropsychiatrica, pages 1-11.
Crossref
Crossref
E. G. Rahim, E. G. Kornetova, A. A. Goncharova, A. N. Кornetov & A. V. Semke. (2022) The effect of antipsychotic-induced extrapyramidal disorders on patient’s compliance with schizophrenia (a clinical case). Bulletin of Siberian Medicine 20:4, pages 211-217.
Crossref
Crossref
Hiroyoshi Takeuchi, Yasuhiro Mori & Yuichiro Tsutsumi. (2022) Pathophysiology, prognosis and treatment of tardive dyskinesia. Therapeutic Advances in Psychopharmacology 12, pages 204512532211173.
Crossref
Crossref
David M. Taylor, Thomas R. E. Barnes & Allan H. Young. 2021. The Maudsley Prescribing Guidelines in Psychiatry. The Maudsley Prescribing Guidelines in Psychiatry
1
224
.
Nina K. Popova, Alexander V. Kulikov & Vladimir S. Naumenko. (2020) Spaceflight and brain plasticity: Spaceflight effects on regional expression of neurotransmitter systems and neurotrophic factors encoding genes. Neuroscience & Biobehavioral Reviews 119, pages 396-405.
Crossref
Crossref
Oscar Patterson-Lomba, Rajeev Ayyagari & Benjamin Carroll. (2019) Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurology 19:1.
Crossref
Crossref
Sattaria Dilks, Rose Mary Xavier, Crystal Kelly & Jessica Johnson. (2019) Implications of Antipsychotic Use. Nursing Clinics of North America 54:4, pages 595-608.
Crossref
Crossref
Saurabh Aggarwal, Michael Serbin & Chuck Yonan. (2019) Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. Journal of Comparative Effectiveness Research 8:13, pages 1077-1088.
Crossref
Crossref
Aaron Pierce & Douglas Coker. (2019) Tardive Dyskinesia Suppression Seen During A Catatonic State: A Case Report. Psychosomatics 60:4, pages 428-431.
Crossref
Crossref
Ece YAZLA & Çiçek HOCAOĞLU. (2019) Tardif Diskinezi için Güncel Tanı ve Tedavi YaklaşımlarıThe Diagnosis And Current Treatment Approaches For The Tardive Dyskinesia. Balıkesir Medical Journal 3:2, pages 73-84.
Crossref
Crossref
James David AdamsJr.Jr.. (2019) Tardive Dyskinesia and Dopamine Oxidation, Cumulative Effects. J 2:2, pages 138-141.
Crossref
Crossref
Roger S. McIntyre, Joseph R. Calabrese, Andrew A. Nierenberg, Khodayar Farahmand, Chuck Yonan, Scott Siegert & Joshua Burke. (2019) The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder. Journal of Affective Disorders 246, pages 217-223.
Crossref
Crossref
Merete Bakke, Tove Henriksen, Heidi Bryde Biernat, Torben Dalager & Eigild Møller. (2018) Interdisciplinary recognizing and managing of drug-induced tardive oromandibular dystonia: two case reports. Clinical Case Reports 6:11, pages 2150-2155.
Crossref
Crossref
Erin Feinstein & Ruth Walker. (2018) An Update on the Treatment of Chorea. Current Treatment Options in Neurology 20:10.
Crossref
Crossref
Ting Yu, Yanli Li, Fengmei Fan, Hongbao Cao, Xingguang Luo, Shuping Tan, Fude Yang, Xiangyang Zhang, Yin Yao Shugart, L. Elliot Hong, Chiang-Shan R. Li & Yunlong Tan. (2018) Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement. Scientific Reports 8:1.
Crossref
Crossref
Mehmet Emin Demirkol, Şilan Şenbayram, Gökçen Doğangüneş & Lut Tamam. (2018) Tardif Diskinezi ve Tedavi Yaklaşımları. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry 10:2, pages 239-254.
Crossref
Crossref
Dao Thai-Cuarto, Christopher F. O’Brien, Roland Jimenez, Grace S. Liang & Joshua Burke. (2017) Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug Safety 41:4, pages 429-440.
Crossref
Crossref
In Won ChungImyel KimTak YounSeong Hoon JeongHee Yeon JungYong Sik Kim. (2018) Antipsychotic-Induced Oculogyric Crisis and Paroxysmal Perceptual Alteration. Korean Journal of Schizophrenia Research 21:1, pages 9.
Crossref
Crossref
Myeong Hwan Bang, Jiseong Hong & Hyoung Seop Kim. (2018) Seven Cases of Successful Remission after Trial of Metoclopramide on Orofacial Dyskinesia of Stroke Patients: a Case Series. Brain & Neurorehabilitation 11:1.
Crossref
Crossref
Vladimir S. Naumenko & Evgeni Ponimaskin. (2018) Palmitoylation as a Functional Regulator of Neurotransmitter Receptors. Neural Plasticity 2018, pages 1-18.
Crossref
Crossref
Dong Xu, Alexandrea G. Ham, Rickey D. Tivis, Matthew L. Caylor, Aoxiang Tao, Steve T. Flynn, Peter J. Economen, Hung K. Dang, Royal W. Johnson & Vaughn L. Culbertson. (2017) MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. EBioMedicine 26, pages 132-137.
Crossref
Crossref
Alcindo Busanello, Caroline Queiroz Leal, Luis Ricardo Peroza, Jivago Röpke, Elizete de Moraes Reis, Catiuscia Molz de Freitas, Milena Libardoni, Nilda Berenice de Vargas Barbosa & Roselei Fachinetto. (2017) Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine. Neurochemical Research 42:11, pages 3033-3040.
Crossref
Crossref
Catherine Lévesque, Giovanni Hernandez, Souha Mahmoudi, Frédéric Calon, Fabrizio Gasparini, Baltazar Gomez-mancilla, Pierre J. Blanchet & Daniel Lévesque. (2017) Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs. Neuroscience 361, pages 43-57.
Crossref
Crossref
Hanna Bergman, Dawn-Marie Walker, Adriani Nikolakopoulou, Karla Soares-Weiser & Clive E Adams. (2017) Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. Health Technology Assessment 21:43, pages 1-218.
Crossref
Crossref
Hubert H. Fernandez, Stewart A. Factor, Robert A. Hauser, Joohi Jimenez-Shahed, William G. Ondo, L. Fredrik Jarskog, Herbert Y. Meltzer, Scott W. Woods, Danny Bega, Mark S. LeDoux, David R. Shprecher, Charles Davis, Mat D. Davis, David Stamler & Karen E. Anderson. (2017) Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology 88:21, pages 2003-2010.
Crossref
Crossref
Karim Selfani, Valérie L. Soland, Sylvain Chouinard & Philippe Huot. (2017) Movement Disorders Induced by the “Atypical” Antipsychotic Aripiprazole. The Neurologist 22:1, pages 24-28.
Crossref
Crossref
Sweta Goel & William Ondo. 2017. Movement Disorders Curricula. Movement Disorders Curricula
283
289
.
Jonathan M. Meyer. (2017) Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia. CNS Spectrums 21:S1, pages 13-24.
Crossref
Crossref
Jamie Talan. (2016) News from the International Congress of Parkinson's Disease and Movement Disorders. Neurology Today 16:14, pages 46-46.
Crossref
Crossref
Sai Krishna J. Munjampalli & Debra E. Davis. (2016) Medicinal-Induced Behavior Disorders. Neurologic Clinics 34:1, pages 133-169.
Crossref
Crossref
Paul P. Lerner, Chanoch Miodownik & Vladimir Lerner. (2015) Tardive dyskinesia (syndrome): Current concept and modern approaches to its management. Psychiatry and Clinical Neurosciences 69:6, pages 321-334.
Crossref
Crossref
N. K. Popova, A. V. Kulikov, E. M. Kondaurova, A. S. Tsybko, E. A. Kulikova, I. B. Krasnov, B. S. Shenkman, E. Yu. Bazhenova, N. A. Sinyakova & V. S. Naumenko. (2014) Risk Neurogenes for Long-Term Spaceflight: Dopamine and Serotonin Brain System. Molecular Neurobiology 51:3, pages 1443-1451.
Crossref
Crossref
Tracy M. Jones, Israt Jahan & Theresa A. Zesiewicz. 2015. Medication-Induced Movement Disorders. Medication-Induced Movement Disorders
72
80
.
Richard M. Kostrzewa & Ryszard Brus. 2016. Neurotoxin Modeling of Brain Disorders—Life-long Outcomes in Behavioral Teratology. Neurotoxin Modeling of Brain Disorders—Life-long Outcomes in Behavioral Teratology
353
362
.
S. Gopal, H. Xu, C. Bossie, J. A. Burón, D. J. Fu, A. Savitz, I. Nuamah & D. Hough. (2014) Incidence of tardive dyskinesia: a comparison of long‐acting injectable and oral paliperidone clinical trial databases. International Journal of Clinical Practice 68:12, pages 1514-1522.
Crossref
Crossref
Seung Ki KimJoon Yeop KimHyoung Seop Kim. (2014) Trial of Metoclopramide on Oro-facial Dyskinesia Following Traumatic Brain Injury: A Case Report. Brain & Neurorehabilitation 7:2, pages 147.
Crossref
Crossref